The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2020 | Irinotecan/cisplatin vs etoposide/cisplatin in resected high-grade neuroendocrine lung carcinoma
Hirotsugu Kenmotsu, MD, of the Shizuoka Cancer Center, Shizuoka, Japan, discusses results from a phase III study comparing relapse free survival of completed resected high grade neuroendocrine carcinoma of the lung patients treated with either irinotecan and cisplatin or etoposide and cisplatin. Dr Kenmotsu reveals no significant difference in relapse free survival between the two different treatment arms. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
